CD3 × CD20 bispecific T-cell engager (specialist)
Epcoritamab
Brand names: Tepkinly
Adult dose
Dose: Step-up SC priming (0.16mg → 0.8mg → 48mg) then 48mg SC weekly per protocol
Route: Subcutaneous
Frequency: Weekly (varies by cycle)
Clinical pearls
- Relapsed/refractory diffuse large B-cell lymphoma (3rd-line) — NICE TA evaluation in progress
- REMS-style pre-medication and CRS monitoring per BSH
- Specialist haemato-oncology centre with CRS expertise
Contraindications
- Active severe infection
- Hypersensitivity
Side effects
- Cytokine release syndrome
- ICANS / neurotoxicity
- Tumour lysis syndrome
- Cytopenias
- Infections (incl. opportunistic)
- Hypogammaglobulinaemia
Interactions
- Live vaccines
- Other immunosuppressives
Monitoring
- FBC
- Cytokines
- Neurological assessment (ICE score)
- Infection
- Immunoglobulins
Reference: BNF; NICE TA evaluation; BSH guidelines; SmPC; https://bnf.nice.org.uk/drugs/epcoritamab-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- C-Peptide to Glucose Ratio · Diabetes Classification
- IMDC (Heng) Score for Metastatic RCC · Renal Cell Carcinoma
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- HCT-CI — Haematopoietic Cell Transplant Comorbidity Index · Risk Stratification
- MSKCC/Motzer Score for Metastatic RCC · Cancer Prognosis
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158